Development and Validation of a Nomogram for Predicting Survival in Gallbladder Cancer Patients With Recurrence After Surgery
- PMID: 33505902
- PMCID: PMC7829964
- DOI: 10.3389/fonc.2020.537789
Development and Validation of a Nomogram for Predicting Survival in Gallbladder Cancer Patients With Recurrence After Surgery
Abstract
Background: The management of gallbladder cancer (GBC) patients with recurrence who need additional therapy or intensive follow-up remains controversial. Therefore, we aim to develop a nomogram to predict survival in GBC patients with recurrence after surgery.
Methods: A total of 313 GBC patients with recurrence from our center was identified as a primary cohort, which were randomly divided into a training cohort (N = 209) and an internal validation cohort (N = 104). In addition, 105 patients from other centers were selected as an external validation cohort. Independent prognostic factors, identified by univariate and multivariable analysis, were used to construct a nomogram. The performance of this nomogram was measured using Harrell's concordance index (C-index) and calibration curves.
Results: Our nomogram was established by four factors, including time-to-recurrence, site of recurrence, CA19-9 at recurrence, and treatment of recurrence. The C-index of this nomogram in the training, internal and external validation cohort was 0.871, 0.812, and 0.754, respectively. The calibration curves showed an optimal agreement between nomogram prediction and actual observation. Notably, this nomogram could accurately stratify patients into different risk subgroups, which allowed more significant distinction of Kaplan-Meier curves than that of using T category. The 3-year post-recurrence survival (PRS) rates in the low-, medium-, and high-risk subgroups from the external validation cohort were 53.3, 26.2, and 4.1%, respectively.
Conclusion: This nomogram provides a tool to predict 1- and 3-year PRS rates in GBC patients with recurrence after surgery.
Keywords: gallbladder cancer; nomogram; prognostic model; recurrence; survival.
Copyright © 2021 Chen, Li, Topatana, Lv, Cao, Hu, Lin, Juengpanich, Shen and Cai.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures





Similar articles
-
A nomogram for predicting cancer-specific survival for elderly patients with gallbladder cancer.BMC Gastroenterol. 2022 Nov 2;22(1):444. doi: 10.1186/s12876-022-02544-y. BMC Gastroenterol. 2022. PMID: 36324087 Free PMC article.
-
Development and Validation of a Nomogram for Early Detection of Malignant Gallbladder Lesions.Clin Transl Gastroenterol. 2019 Oct;10(10):e00098. doi: 10.14309/ctg.0000000000000098. Clin Transl Gastroenterol. 2019. PMID: 31663905 Free PMC article.
-
Development and validation of a nomogram prediction model based on albumin-to-alkaline phosphatase ratio for predicting the prognosis of gallbladder carcinoma.Pathol Oncol Res. 2023 Jan 4;28:1610818. doi: 10.3389/pore.2022.1610818. eCollection 2022. Pathol Oncol Res. 2023. PMID: 36685104 Free PMC article.
-
A novel prognostic nomogram for colorectal cancer liver metastasis patients with recurrence after hepatectomy.Cancer Med. 2021 Mar;10(5):1535-1544. doi: 10.1002/cam4.3697. Epub 2021 Feb 4. Cancer Med. 2021. PMID: 33539664 Free PMC article.
-
A Nomogram for Prediction of Overall Survival in Patients with Node-negative Gallbladder Cancer.J Cancer. 2019 Jun 2;10(14):3246-3252. doi: 10.7150/jca.30046. eCollection 2019. J Cancer. 2019. PMID: 31289596 Free PMC article.
Cited by
-
ANLN Promotes the Proliferation and Migration of Gallbladder Cancer Cells via STRA6-Mediated Activation of PI3K/AKT Signaling.Cancers (Basel). 2024 Feb 11;16(4):752. doi: 10.3390/cancers16040752. Cancers (Basel). 2024. PMID: 38398143 Free PMC article.
-
Molecular biomarkers involved in the progression of gallbladder inflammatory lesions to invasive cancer: A proteomic approach.Biomol Biomed. 2024 Dec 11;25(1):115-143. doi: 10.17305/bb.2024.10704. Biomol Biomed. 2024. PMID: 39284282 Free PMC article.
-
Bortezomib-Encapsulated Dual Responsive Copolymeric Nanoparticles for Gallbladder Cancer Targeted Therapy.Adv Sci (Weinh). 2022 Mar;9(7):e2103895. doi: 10.1002/advs.202103895. Epub 2022 Jan 23. Adv Sci (Weinh). 2022. PMID: 35068071 Free PMC article.
-
Pre-activated nanoparticles with persistent luminescence for deep tumor photodynamic therapy in gallbladder cancer.Nat Commun. 2023 Sep 14;14(1):5699. doi: 10.1038/s41467-023-41389-1. Nat Commun. 2023. PMID: 37709778 Free PMC article.
-
A validated nomogram integrating baseline peripheral T-lymphocyte subsets and NK cells for predicting survival in stage I-IIIA non-small cell lung cancer after resection.Ann Transl Med. 2022 Mar;10(5):250. doi: 10.21037/atm-21-6347. Ann Transl Med. 2022. PMID: 35402593 Free PMC article.
References
-
- Yee K, Sheppard BC, Domreis J, Blanke CD. Cancers of the gallbladder and biliary ducts. Oncol (Williston Park) (2002) 16(7):939–46, 49; discussion 49-50, 52-3, 56-7. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources